Background: The global outbreak of COVID-19 has raised concerns about its potential impact on the management of chronic health conditions, particularly diabetes. Objectives: This cross-sectional study was conducted to assess the effect of COVID-19 on blood sugar control and lipid profiles in individuals with type 2 diabetes. Methods: This cross-sectional study gathered and analyzed data from 61 diabetic patients between March 2021 and March 2022. Data collected included demographic information, HbA1c levels, and lipid profiles, all obtained from the files at the Endocrine and Metabolism Clinic of Kowsar Hospital. Results: Among the 61 patients with complete data, 12 (19.7%) tested positive for COVID-19. Statistical analysis revealed no significant differences between the COVID-19 positive and negative groups in terms of age (P = 0.759), HbA1c level (P = 0.209), total cholesterol level (P = 0.841), triglyceride levels (P = 0.876), HDL (P = 0.504), LDL (P = 0.191), or duration of diabetes treatment (P = 0.779). However, significant differences were found between male and female diabetic patients in age (P = 0.030) and total cholesterol levels (P = 0.030), with women being older and having higher total cholesterol. No significant differences were observed between groups treated with oral medication and insulin in terms of age (P = 0.789), HbA1c level (P = 0.584), total cholesterol level (P = 0.263), triglyceride levels (P = 0.162), HDL (P = 0.718), LDL (P = 0.463), or duration of diabetes treatment (P = 0.545). Conclusions: The findings indicate that COVID-19 did not significantly affect glycemic control or lipid profiles in the studied diabetic population. The observed associations between demographic and clinical factors offer valuable insights into the complex relationship between diabetes and COVID-19.